Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for ...

A new federal study is linking the ability to quit smoking with longer-term success from the grip of drug or alcohol ...

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the ...

The FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S. The drug was ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill brensocatib, which will be sold under the brand ...

Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to a potential multibillion ...